Share Price | StemCell Institute Stock Analysis & Recommendation

Results Declared: StemCell Institute has declared results on 06 Aug 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Compare StemCell Institute with Similar Stocks

SUSMED, Inc.GNI Group Ltd.Peptidream, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

The company has declared Negative results for the last 6 consecutive quarters

INTEREST(HY) At JPY 3.06 MM has Grown at 27.41%
NET PROFIT(HY) At JPY 45.33 MM has Grown at -49.04%
ROCE(HY) Lowest at 5.46%

With ROE of 7.15%, it has a very expensive valuation with a 2.57 Price to Book Value

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

JPY 7,521 Million (Micro Cap)

P/E

36.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.89

Return on Equity

4.88%

Price to Book

2.80

Revenue and Profits:

Net Sales:

722 Million

(Quarterly Results - Jun 2026)

Net Profit:

10 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

1.23%

6 Months

-14.07%

1 Year

-26.03%

2 Years

-53.7%

3 Years

-71.87%

4 Years

-84.7%

5 Years

-84.51%

StemCell Institute for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

13.76%

EBIT Growth (5y)

14.05%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-1.03

Sales to Capital Employed (avg)

0.91

Tax Ratio

39.85%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

68.50%

ROE (avg)

10.52%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.57

EV to EBIT

15.31

EV to EBITDA

10.02

EV to Capital Employed

49.85

EV to Sales

1.53

PEG Ratio

Dividend Yield

ROCE (Latest)

325.66%

ROE (Latest)

7.15%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2026 is 8.20% vs -8.45% in Mar 2026",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2026 is 177.04% vs -122.65% in Mar 2026",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'26",
        "Mar'26",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "722.00",
          "val2": "667.30",
          "chgp": "8.20%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "85.40",
          "val2": "29.70",
          "chgp": "187.54%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.60",
          "val2": "1.50",
          "chgp": "6.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "10.40",
          "val2": "-13.50",
          "chgp": "177.04%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "56.70%",
          "val2": "-23.70%",
          "chgp": "8.04%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2026 is 4.93% vs 7.98% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2026 is -66.04% vs 24.05% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,811.30",
          "val2": "2,679.20",
          "chgp": "4.93%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "359.40",
          "val2": "546.30",
          "chgp": "-34.21%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "5.40",
          "val2": "1.20",
          "chgp": "350.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "131.00",
          "val2": "385.80",
          "chgp": "-66.04%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "72.10%",
          "val2": "156.20%",
          "chgp": "-8.41%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ

Jun'26

Mar'26

Change(%)

Net Sales

722.00

667.30

8.20%

Operating Profit (PBDIT) excl Other Income

85.40

29.70

187.54%

Interest

1.60

1.50

6.67%

Exceptional Items

0.00

Consolidate Net Profit

10.40

-13.50

177.04%

Operating Profit Margin (Excl OI)

56.70%

-23.70%

8.04%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2026 is 8.20% vs -8.45% in Mar 2026

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2026 is 177.04% vs -122.65% in Mar 2026

All Quarterly Results

Annual Results Snapshot (Consolidated) - Mar'26

Mar'26

Mar'25

Change(%)

Net Sales

2,811.30

2,679.20

4.93%

Operating Profit (PBDIT) excl Other Income

359.40

546.30

-34.21%

Interest

5.40

1.20

350.00%

Exceptional Items

0.00

Consolidate Net Profit

131.00

385.80

-66.04%

Operating Profit Margin (Excl OI)

72.10%

156.20%

-8.41%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2026 is 4.93% vs 7.98% in Mar 2025

Consolidated Net Profit

YoY Growth in year ended Mar 2026 is -66.04% vs 24.05% in Mar 2025

All Annual Results

Company CV

About StemCell Institute

StemCell Institute

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available